Compare AbbVie Inc (ABBV) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Union Pacific Corporation — how do they compare? AbbVie Inc trades at $248.65 (market cap $441.94B), while Union Pacific Corporation trades at $292.18 (market cap $173.99B). The key difference: AbbVie Inc is far larger — about 2.5× Union Pacific Corporation's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | UNP | |
|---|---|---|
Market Cap | $441.94B | $173.99B |
Sector | Health | Industrials |
52-Week High | $263.58 | $307.32 |
52-Week Low | $197.38 | $214.91 |
Enterprise Value | $506.19B | $203.04B |
Dividend Yield | 2.77% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Union Pacific (UNP) trades at $292.24, down 0.3% on the day, with a neutral technical signal. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised full-year guidance. Fundamentals remain robust with a net income margin of 28.85% and ROE of 39.7%, though valuation ratios like P/E of 23.71 are elevated. Recent news highlights a 3% dividend increase and ongoing merger developments with Norfolk Southern.
The outlook is positive, driven by service-led growth, pricing power, and efficiency gains. Key opportunities include domestic intermodal expansion and margin improvement. Risks involve high fuel costs, regulatory scrutiny of the merger, and economic sensitivity. Analyst consensus is bullish with a $334.33 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
